Saturday 17 October 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.58
0.04
−6.45%
Follow APRE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(79.36%) | (79.37%) | (41.85%) | (47.44%) | |
| (63.27%) | (63.14%) | (35.25%) | (41.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(115.10%) | (98.00%) | (28.46%) | (31.65%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(2.11) | (1.97) | (0.82) | (0.23) | |
Free Cash Flow |
(13.44) | (12.89) | (12.02) | (12.19) | |
Capital Expenditures |
— | — | — | (0.02) | |
| Other line items | |||||
Cash ROIC |
(54.58%) | (47.68%) | (13.65%) | (15.30%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,719.23% | 2,465.17% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,210.94% | 2,266.92% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
101.41% | 167.34% | 0.00% | 0.00% | |
Operating CF/Net income |
1.03 | 1.02 | 1.01 | 0.99 | |
Depreciation/Fixed assets |
0.33 | 0.36 | 0.40 | 0.34 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (1.04) | |
Revenue per Share |
0.08 | 0.04 | 0.00 | 0.00 | |
Operating CF per Share |
(2.11) | (1.97) | (0.82) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates